nonalcoholic steatohepatitis
Akero fails to meet NASH trial endpoint, hurting other players in the field
Anika Sharma
The landscape of Nonalcoholic Steatohepatitis (NASH) appeared promising with Madrigal Therapeutics taking steps toward treatment approval. However, this optimism was ...
Intercept Pharmaceuticals, After 2 FDA Setbacks and Restructuring Efforts, Finds a Buyer in Italy’s Alfasigma
Anika Sharma
Intercept Pharmaceuticals has faced substantial challenges over the past three years, particularly after the FDA rejected its attempts to bring ...
Inventiva and Kezar partner with Asian biotechs to advance NASH and lupus drugs
Anika Sharma
In a strategic move, Inventiva and Kezar Life Sciences have successfully secured buyers for the Asian rights to their lead ...
Madrigal’s NASH drug gets fast-track review from FDA, no panel needed
Anika Sharma
In the wake of a recent CEO transition, Madrigal Pharmaceuticals has disclosed that its nonalcoholic steatohepatitis (NASH) drug has been ...
Kriya Acquires Gene Therapy Biotech To Enter NASH Market With Novel Approach
Anika Sharma
Kriya Therapeutics, a prominent player in the biotech industry, has continued its acquisition spree, this time securing Tramontane Therapeutics to ...
